NICE says yes to Roche's MabThera for relapsed or refractory CLL
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence, looks poised to recommend Roche's anti-CD20 drug MabThera (rituximab) for treating certain patients with relapsed or refractory chronic lymphocytic leukaemia (CLL).
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.